LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Elenco Azioni・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

181.58 9.67

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

165.57

Massimo

187.84

Metriche Chiave
By Trading Economics
Entrata	-332M -277M
Vendite	-11M 994M
Margine di Profitto	-27.816
Dipendenti	18,300
EBITDA	730K 198M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+14.5% upside

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	562M 8.5B
Apertura precedente	171.91
Chiusura precedente	181.58

Notizie sul Sentiment di mercato

By Acuity

19%

81%

36 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

117.16 / 144.77 Supporto e resistenza

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 mag 2026, 23:41 UTC

Utili

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mag 2026, 21:40 UTC

Utili

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mag 2026, 23:34 UTC

Discorsi di Mercato

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mag 2026, 23:13 UTC

Utili

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mag 2026, 23:13 UTC

Utili

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mag 2026, 23:12 UTC

Utili

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mag 2026, 23:11 UTC

Utili

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mag 2026, 23:07 UTC

Utili

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mag 2026, 23:06 UTC

Utili

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mag 2026, 23:06 UTC

Utili

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mag 2026, 23:05 UTC

Utili

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mag 2026, 23:04 UTC

Utili

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mag 2026, 22:50 UTC

Utili

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mag 2026, 22:25 UTC

Discorsi di Mercato

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mag 2026, 22:11 UTC

Utili

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mag 2026, 22:11 UTC

Utili

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mag 2026, 22:05 UTC

Discorsi di Mercato

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mag 2026, 21:58 UTC

Utili

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mag 2026, 21:47 UTC

Discorsi di Mercato

Utili

Costco Posts 13% Sales Growth in April -- Market Talk

6 mag 2026, 21:46 UTC

Utili

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mag 2026, 21:40 UTC

Utili

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mag 2026, 21:35 UTC

Discorsi di Mercato

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mag 2026, 21:32 UTC

Azioni calde

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mag 2026, 21:29 UTC

Utili

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

14.5% in crescita

Previsioni per 12 mesi

Media 197.3 USD 14.5%

Alto 235 USD

Basso 160 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

36 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.